How should pulmonary hypertension associated with an atrial septal defect (ASD) or Eisenmenger syndrome be treated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Pulmonary Hypertension in ASD/Eisenmenger Disease

For symptomatic adults with Eisenmenger syndrome due to ASD, start with bosentan as first-line therapy, as it has the strongest evidence (Class I, Level A recommendation) for improving functional capacity and hemodynamics 1.

Initial Diagnostic Confirmation

Before initiating treatment, you must confirm the diagnosis through cardiac catheterization—echocardiography alone is insufficient for accurate assessment of pulmonary pressures and vascular resistance 1. Specifically exclude other causes of right-to-left shunting including:

  • Severe pulmonary hypertension from thromboembolic or rheumatic disease
  • Subpulmonary chamber outflow obstruction
  • Abnormalities of subpulmonary chamber compliance
  • Vascular streaming 1

This distinction is critical because PAH-specific therapies will not work if the shunting is due to RVOT obstruction rather than true Eisenmenger physiology.

Medical Treatment Algorithm

First-Line Therapy

  • Bosentan (endothelin receptor antagonist) is the only Class I, Level A recommendation for symptomatic Eisenmenger syndrome with ASD or VSD 1
  • Randomized controlled trials demonstrate improved 6-minute walk distance, hemodynamics, and functional capacity after 4 months 1
  • Long-term benefit confirmed in open-label extensions and registry data 1

Second-Line Options

If monotherapy with bosentan provides inadequate symptomatic improvement:

  • Add PDE-5 inhibitors (sildenafil or tadalafil) to bosentan (Class IIa, Level B-R) 1
  • Combination therapy improves systemic arterial saturation and may enhance 6-minute walk testing and hemodynamics 1

Alternative Monotherapy

PDE-5 inhibitors alone (sildenafil or tadalafil) are reasonable as monotherapy for symptomatic Eisenmenger syndrome with ASD, VSD, or great artery shunt (Class IIa, Level B-NR) 1

Special Considerations

For Complex Lesions or Down Syndrome

Bosentan remains reasonable therapy for Eisenmenger syndrome with:

  • Shunts other than ASD/VSD (e.g., PDA, aortopulmonary window)
  • Complex congenital heart lesions
  • Down syndrome (Class IIa, Level B-NR to C-EO) 1

Palliative Measures

Consider these adjunctive therapies, though evidence is limited:

  • Supplemental oxygen only if it empirically increases arterial oxygen saturation and reduces symptoms 1
  • Systemic anticoagulation in cases of pulmonary artery thrombosis or heart failure signs (Class IIa, Level C), but recognize increased bleeding risk 2
  • Phlebotomy with isovolumic replacement when hematocrit exceeds 65% and hyperviscosity symptoms are present 2

Avoid These Interventions

  • Calcium channel blockers are NOT recommended in Eisenmenger syndrome (Class III, Level C) 2
  • ASD closure is contraindicated when PAP >2/3 systemic, PVR >2/3 systemic, or net right-to-left shunt exists 3

"Treat-and-Repair" Strategy

Recent case reports suggest that in highly selected patients who demonstrate marked hemodynamic improvement with aggressive PAH-specific therapy, fenestrated ASD closure may become feasible 4, 5, 6. However, this approach:

  • Requires multidisciplinary team expertise in both CHD and PAH 1
  • Demands significant reduction in pulmonary pressure and vascular resistance before considering closure
  • Should only be attempted after prolonged medical optimization (often years)
  • Remains investigational and not part of standard guidelines

Advanced Therapies

For patients failing maximal medical therapy:

  • Lung transplantation with cardiac defect repair or heart-lung transplantation should be considered soon after inadequate response to maximal combination therapy (Class I, Level C) 7
  • Balloon atrial septostomy may be considered where available after failure of maximal medical therapy (Class IIb, Level C) 7

Critical Pitfalls to Avoid

  1. Do not rely on echocardiography alone for treatment decisions—cardiac catheterization with careful hemodynamic measurements is fundamental 1

  2. Do not attempt defect closure in established Eisenmenger syndrome with standard criteria—this worsens outcomes and is contraindicated 3

  3. Avoid circumstances that worsen symptoms: high altitude, pregnancy, extreme heat/humidity causing vasodilation, nephrotoxin exposure, extreme exertion, large intravascular volume shifts 1

  4. Recognize that even after successful medical therapy, modest residual PAH substantially determines intermediate and long-term outcomes—lifelong follow-up is mandatory 1

The evidence strongly supports bosentan as first-line therapy, with PDE-5 inhibitors as reasonable alternatives or additions for combination therapy. This represents a significant shift from the historical nihilism surrounding Eisenmenger syndrome, though the condition remains serious with limited curative options beyond transplantation.

References

Related Questions

What medications are appropriate for treating a cough in a patient with Eisenmenger syndrome and pulmonary hypertension?
What criteria are used to assess operability for surgical closure of left‑to‑right shunt lesions in patients with pulmonary hypertension?
How should fetal wellbeing be monitored in a pregnancy with a single umbilical artery?
What are the recommended surveillance and management strategies for a pregnant patient with a single uterine artery?
In a patient with pelvic inflammatory disease who cannot tolerate metronidazole, what alternative anaerobic agent and treatment regimen should be used?
What is the appropriate management for possible focal irritation or impingement of the right L5 nerve root in the subarticular recess at the L4/L5 level due to a disc bulge, with an incidental sacral Tarlov cyst?
What are the plasma half‑life of aspirin and the half‑life of clopidogrel (Plavix) and its active metabolite?
Can tinidazole be used as an alternative to metronidazole for anaerobic coverage in a patient with pelvic inflammatory disease who cannot tolerate metronidazole?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.